Your browser doesn't support javascript.
loading
Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.
Meng, Hongxue; Huang, Lan; Wang, Jiahui; Zhou, Yingxu; Wang, Meng; Yang, Zhaoyang; Hong, Xuan.
Afiliação
  • Meng H; Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Huang L; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Wang J; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Zhou Y; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Wang M; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Yang Z; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Hong X; Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Int J Clin Pract ; 75(12): e14877, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34525256
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores ErbB / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores ErbB / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article